.STUDY HIGHLIGHT.06 August 2024.
A large randomized regulated test along with cisgender ladies highlights the obstacles of fidelity to a daily oral preexposure treatment program as well as shows that twice-yearly treatment of lenacapavir may keep efficient HIV deterrence levels over 6 months.